Yazar "Ergin, Elif" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Yayın
    A pilot investigation on possible interactions between clinical parameters and the psychology of couples undergoing IVF
    (Wiley, 2025) Aydın, Gerçek; Bülbül, Mehmet; Ergin, Elif; Aydin, Ayşe Gül; Akkaya, Cengiz; Hatırnaz, Şafak; Tinelli, Andrea
    Objective: To investigate the potential reciprocal influences between in vitro fertiliza tion (IVF) and the psychological states of patients. Materials and Methods: A prospective cohort study involved 180 couples who sought consultation for IVF. To monitor the fluctuations in the emotional states of the cou ples throughout the IVF process, questionnaires were administered on two separate occasions: the first was conducted immediately before the initiation of medication, and the second was administered promptly following the completion of embryo trans fer. The BECK inventories for anxiety and depression were employed for evaluation. Pregnancy outcomes were exclusively analyzed for women who received high-quality blastocysts, with cleavage-stage embryo transfers being excluded from consideration. Results: Pregnancy rates did not significantly differ based on the presence of height ened anxiety and/or depression among couples. Notably, a correlation was identified between severe anxiety in women before IVF and diminished rates of fertilization, as well as lower blastocyst/oocyte and blastocyst/metaphase II (M2) ratios (8.7 ± 5.0 vs. 7.5 ± 6.1, P= 0.029; 0.284 ± 0.199 vs. 0.218 ± 0.209, P= 0.001; and 0.333 ± 0.209 vs. 0.272 ± 0.232, P= 0.016, respectively). In the male cohort, elevated anxiety scores, ei ther pre- or post-IVF treatment, were found to be linked with a reduced mean oocyte count, as well as lower rates of M2, fertilization, blastocyst, and total embryo counts (P< 0.05). Conclusions: Pregnancy rates were not affected by the presence of anxiety and de pression, as they do not exert a significant impact on the implantation success of blas tocysts. However, given that fertilization rates are statistically diminished in instances of severe anxiety, which consequently results in a reduced number of blastocysts and total embryos, a decline in cumulative pregnancy rates may be anticipated.
  • Küçük Resim
    Yayın
    Considering its mechanism of action it may be logical to choose letrozole as an initial option for endometrium preparation before vitrified-warmed embryo transfer
    (Wiley, 2025) Aydın, Gerçek; Aslan, Kiper; Araç, Merve; Ergin, Elif; Kasapoğlu, Işıl; Uncu, Gürkan
    Aim: To assess the efficacy of letrozole and programmed hormone replacement therapy (HRT) cycles in terms of obstetric outcomes for women undergoing a single vitrified-warmed blastocyst embryo transfer (SVBT). Methods: This study is a retrospective study conducted in a private IVF (in vitro fertilization) clinic. A total of 324 FET cycles (letrozole group = 183, HRT = 141), consisting of primary infertile patients aged <40 years, were enrolled. The cycle characteristics, pregnancy results, and perinatal parameters were recorded. The primary outcomes of this study are pregnancy and miscarriage rates, live birth rates, whereas hypertensive disease of pregnancy (HDP), intrauterine growth restriction (IUGR) and preterm birth are the secondary outcomes. Results: Positive β-HCG rates were 53% (97/183) versus 61% (86/141), whereas clinical pregnancy rates were 47% (86/183) versus 51.1% (72/141) for the letrozole and HRT groups, respectively. For clinical miscarriage, the results were 6.5% (12/183) for letrozole versus 15.6% (22/141) for HRT groups, which were statistically significant. For live birth rate (LBR), letrozole was found to be slightly better compared to HRT 40.4% (74/183) versus 35.5% (50/141). Considering the perinatal outcomes, the parameters were comparable between the groups. Conclusions: In terms of perinatal outcomes and IVF success, letrozole was not found to be inferior to HRT. Letrozole can be utilized as a safe and effective agent, even as a first-line treatment, given the potential benefits offered by its mechanism of action and being a reasonable option for both ovulatory and unovulatory patients.